Novel Targets for the Treatment of Melanoma

被引:18
作者
Ambrosi, Lara [1 ]
Khan, Shaheer [2 ]
Carvajal, Richard D. [2 ]
Yang, Jessica [2 ]
机构
[1] Stony Brook SOM, 101 Nicholls Rd, Stony Brook, NY 11794 USA
[2] Columbia Univ, Med Ctr, Div Hematol Oncol, 177 Ft Washington Ave,MHB 6GN-435, New York, NY 10032 USA
关键词
Melanoma; Immunotherapy; Checkpoint inhibitors; CTLA-4; PD-1; PD-L1; Targeted therapy; MEK inhibitor; BRAF inhibitor; Oncolytic therapy; TUMOR-INFILTRATING LYMPHOCYTES; LONG-TERM SURVIVAL; ADOPTIVE CELL THERAPY; OPEN-LABEL PHASE-3; CD8(+) T-CELLS; METASTATIC MELANOMA; IMMUNE CHECKPOINT; ANTITUMOR-ACTIVITY; KINASE INHIBITOR; BRAF INHIBITION;
D O I
10.1007/s11912-019-0849-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of Review In this article, we will briefly review the current treatment landscape for metastatic melanoma and provide a comprehensive update on emerging novel treatment strategies. Recent Findings Over the past decade, remarkable advances in immunotherapy and targeted therapy have greatly improved outcomes for patients with advanced melanoma. Although a subset of patients is able to achieve durable responses, the majority experience eventual disease progression on existing therapies. Trials evaluating novel combinatorial strategies, checkpoint inhibitors, immune agonists, T cell-based therapies, intratumoral agents, and others are ongoing. While strides have been made in the treatment of advanced melanoma, further research is needed to identify alternative immune and molecular targets in order to overcome resistance and achieve better clinical outcomes.
引用
收藏
页数:16
相关论文
共 152 条
  • [1] The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial
    Algazi, A. P.
    Cha, E.
    Ortiz-Urda, S. M.
    McCalmont, T.
    Bastian, B. C.
    Hwang, J.
    Pampaloni, M. H.
    Behr, S.
    Chong, K.
    Cortez, B.
    Quiroz, A.
    Coakley, F.
    Liu, S.
    Daud, A. I.
    [J]. BRITISH JOURNAL OF CANCER, 2015, 112 (08) : 1326 - 1331
  • [2] SWOG S1221: A phase 1 dose escalation study co-targeting MAPK-dependent and MAPK-independent BRAF inhibitor resistance in BRAF mutant advanced solid tumors with dabrafenib, trametinib, and GSK2141795 (ClinicalTrials.gov NCT01902173).
    Algazi, Alain Patrick
    Moon, James
    Chmielowski, Bartosz
    Lo, Roger
    Kendra, Kari Lynn
    Lao, Christopher D.
    Lewis, Karl D.
    Gonzalez, Rene
    Kim, Kevin
    Godwin, John E.
    Curti, Brendan D.
    Othus, Megan
    Ribas, Antoni
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets
    Allard, Bertrand
    Longhi, Maria Serena
    Robson, Simon C.
    Stagg, John
    [J]. IMMUNOLOGICAL REVIEWS, 2017, 276 (01) : 121 - 144
  • [4] Targeting A2 adenosine receptors in cancer
    Allard, David
    Turcotte, Martin
    Stagg, John
    [J]. IMMUNOLOGY AND CELL BIOLOGY, 2017, 95 (04) : 333 - 339
  • [5] Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
    Anderson, Ana C.
    Joller, Nicole
    Kuchroo, Vijay K.
    [J]. IMMUNITY, 2016, 44 (05) : 989 - 1004
  • [6] LAG3 (CD223) as a cancer immunotherapy target
    Andrews, Lawrence P.
    Marciscano, Ariel E.
    Drake, Charles G.
    Vignali, Dario A. A.
    [J]. IMMUNOLOGICAL REVIEWS, 2017, 276 (01) : 80 - 96
  • [7] [Anonymous], AACR ANN M 2019
  • [8] [Anonymous], J CLIN ONCOL
  • [9] [Anonymous], EPACADOSTAT E PLUS P
  • [10] [Anonymous], AACR P